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Objective: Neuronal channelopathies cause brain disorders, including epilepsy, migraine, and ataxia. Despite the de-
velopment of mouse models, pathophysiological mechanisms for these disorders remain uncertain. One particularly
devastating channelopathy is Dravet syndrome (DS), a severe childhood epilepsy typically caused by de novo domi-
nant mutations in the SCN1A gene encoding the voltage-gated sodium channel Nav1.1. Heterologous expression of
mutant channels suggests loss of function, raising the quandary of how loss of sodium channels underlying action
potentials produces hyperexcitability. Mouse model studies suggest that decreased Nav1.1 function in interneurons
causes disinhibition. We aim to determine how mutant SCN1A affects human neurons using the induced pluripotent
stem cell (iPSC) method to generate patient-specific neurons.
Methods: Here we derive forebrain-like pyramidal- and bipolar-shaped neurons from 2 DS subjects and 3 human
controls by iPSC reprogramming of fibroblasts. DS and control iPSC-derived neurons are compared using whole-cell
patch clamp recordings. Sodium current density and intrinsic neuronal excitability are examined.
Results: Neural progenitors from DS and human control iPSCs display a forebrain identity and differentiate into bipo-
lar- and pyramidal-shaped neurons. DS patient-derived neurons show increased sodium currents in both bipolar- and
pyramidal-shaped neurons. Consistent with increased sodium currents, both types of patient-derived neurons show
spontaneous bursting and other evidence of hyperexcitability. Sodium channel transcripts are not elevated, consist-
ent with a post-translational mechanism.
Interpretation: These data demonstrate that epilepsy patient–specific iPSC-derived neurons are useful for modeling
epileptic-like hyperactivity. Our findings reveal a previously unrecognized cell-autonomous epilepsy mechanism
potentially underlying DS, and offer a platform for screening new antiepileptic therapies.
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Neuronal ion channelopathies due to genetic mutationscomprise a constellation of central and peripheral
nervous system disorders that manifest as epilepsy, migraine,
ataxia, abnormal pain sensation, or anosmia (reviewed in
Catterall et al1 and Kullmann and Waxman2). Although the
affected genes and involved neuronal subtypes are often
known, the pathophysiological mechanisms underlying
most of these disorders remain poorly understood. One
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such disorder is Dravet syndrome (DS), a devastating child-
hood-onset epilepsy typically characterized by multiple
pharmacoresistant seizure types, cognitive regression, ataxia,
and increased mortality.3,4 In >70% of cases, DS is caused
by de novo mutations in the SCN1A gene which encodes
the a subunit of the neuronal voltage-gated sodium channel
Nav1.1.
5,6 Voltage-gated sodium channels underlie
action potentials in excitable cells such as neurons and myo-
cytes. DS is thought to be caused by SCN1A haploin-
sufficiency,7–9 raising the question of how a partial loss
of sodium channel expression leads to neuronal
hyperexcitability.
The effects of human DS SCN1A mutations or dele-
tions of mouse Scn1a have been studied in heterologous
expression systems and transgenic mouse models,10–13 but
not in human neurons. The opportunity to study the effects
of neuronal ion channel gene mutations in patient-specific
neurons is now available using the induced pluripotent stem
cell (iPSC) technique. This method involves reprogram-
ming somatic cells, such as fibroblasts, using defined genetic
factors to generate PSCs, and it has been accomplished in
mice, humans, and other species.14–17 Recently, the effects
of ion channel gene mutations have been studied in patient-
specific cardiac myocytes generated from iPSCs, and these
reports suggest that the patient-specific cells effectively
model aspects of genetic cardiac arrhythmias.18–20 However,
this approach has not yet been applied to the study of
human neuronal ion channelopathies.
Here we describe a splice donor site mutation21 in
the SCN1A gene of a 7-year-old DS patient. This mutation
results in an abnormal transcript that skips exon 14.
Expression of the mutant SCN1A cDNA in heterologous
systems resulted in little to no Nav1.1 protein and no de-
tectable sodium current. We established human iPSC lines
from the fibroblasts of this DS patient, 1 additional DS
patient with a nonsense mutation, and 3 human controls.
We generated forebrain-like neurons from DS and control
iPSCs and found increased sodium current density in py-
ramidal- and bipolar-shaped neurons from both DS
patients. This increased sodium current density was associ-
ated with spontaneous bursting and other evidence of
epileptic-like hyperexcitability in DS patient neurons. Our
results using patient-derived neurons suggest an unex-
pected pathophysiological mechanism underlying epilepsy
in DS, and demonstrate that iPSC models of DS and other
neuronal ion channelopathies will be useful for exploring
disease pathogenesis and identifying novel therapies.
Subjects and Methods
Expression Vectors
Human Nav1.1 cDNA in pCDM8 was described previously.
22
The IVS1413A>T mutation was introduced into this vector
using the Quick Change XL Kit (Stratagene, La Jolla, CA).
Bacteria-containing plasmids were grown at low temperature to
reduce rearrangements as described.22 Wild-type and mutant
cDNAs were sequenced completely before use.
Western Blot Analysis
tsa-201 cells (maintained at 37C with 5% CO2) were cultured
with Dulbecco modified Eagle medium (DMEM)/F12 medium
supplemented with 10% heat-inactivated fetal bovine serum
and 100U1 100lg/ml penicillin/streptomycin (all from Invi-
trogen, Carlsbad, CA) in poly-D-Lysine–pretreated 10cm
dishes. Cells were mock-transfected or transfected at 60 to 70%
confluency with pCDM8 vectors encoding wild-type or mutant
human Nav1.1 cDNA using the CaPO4 method as described.
22
Transfected cells at 100% confluence were prepared for Western
blot as described.23 Proteins were separated by sodium dodecyl
sulfate polyacrylamide gel electrophoresis on 5% polyacrylamide
gels, transferred to nitrocellulose, and analyzed using the SNAP
i.d. apparatus (Millipore, Billerica, MA) per the manufacturer’s
instructions. Primary antibodies were rabbit anti–pan sodium
channel (1:1,000; Sigma, St Louis, MO) and mouse anti–a-
tubulin monoclonal (1:5,000; Cedarlane Laboratories, Burling-
ton, NC). Secondary antibodies were horseradish peroxidase–
conjugated goat antirabbit or antimouse (1:2,000; Pierce, Rock-
ford, IL). Immunoreactive signals were quantified using ImageJ
(National Institutes of Health) and normalized to a-tubulin
loading control.
Electrophysiological Recordings
For recordings of cultured oocytes, human Nav1.1 wild-type or
IVS1413A>T mutant cDNAs in pCDM8 were linearized with
ScaI and mRNA synthesized using the T7 mMessage mMa-
chine RNA Synthesis Kit (Ambion, Austin, TX). Transcripts
were injected into Xenopus oocytes, and expressed sodium cur-
rents were analyzed by 2-electrode voltage clamp as described.24
Published methods for mRNA analysis, frog maintenance, and
oocyte retrieval were used.24 iPSC-derived neurons were ana-
lyzed by whole-cell patch clamp recordings. Voltage clamp
recordings were performed in the standard whole-cell configura-
tion, using previously described conditions.25 Isolated sodium
currents were recorded from single neurons (bipolar or pyrami-
dal) at room temperature (21–22C) in the presence of a bath
solution containing (in millimolar): 120 NaCl, 1 BaCl2, 2
MgCl2, 0.2 CdCl2, 1 CaCl2, 10 HEPES, 20 TEA-Cl, and 10
glucose (pH5 7.35 with CsOH; osmolarity5 300–305mosm).
Fire-polished patch pipettes were filled with an internal solution
containing (in millimolar): 1 NaCl, 150 N-methyl-D-gluca-
mine, 10 ethyleneglycoltetraacetic acid (EGTA), 2 MgCl2, 40
HEPES, and 25 phosphocreatine-tris, 2 MgATP, 0.02 Na2GTP,
0.1 leupeptin (pH5 7.2 with H2SO4). All recordings were per-
formed within 10 to 120 minutes after the culture medium was
replaced by bath recording solution and the dish with cells was
placed on the recording setup. For current-clamp recordings of
action potentials in iPSC-derived neurons, patch pipettes were
filled with internal solution consisting of (in millimolar): 135
K-gluconate, 4 NaCl, 0.5 CaCl2, 10 HEPES, 5 EGTA, 2 Mg-
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ATP, and 0.4 GTP (pH5 7.3, adjusted with KOH). iPSCs
were bathed in a solution consisting of (in millimolar): 115
NaCl, 2.5 KCl, 1 MgCl2, 1.25 KH2PO4, 26 NaHCO3, 2
CaCl2, 10 HEPES, and 10 D-glucose (pH5 7.4, adjusted with
NaOH). Action potentials were evoked from resting membrane
potential by injection of a series of increasing 1-millisecond
depolarizing currents (0.02nA increments) beginning at sub-
threshold level and rising until action potentials were consis-
tently generated. The threshold potential was defined as the
membrane potential at which these ascending current steps first
initiated an action potential, and was measured at the end of
the depolarizing pulse and the initiation point of the action
potential. Repetitive spiking was evoked by injection of a
1,500-millisecond depolarizing current (0.02nA) from a holding
potential at resting levels.
Generation of iPSCs and Patient-Specific
Neurons
DS patient and control skin biopsy-derived fibroblast cultures
were obtained from the Cleveland Clinic under a protocol
approved by the institutional review board. Retroviral vectors
(pMXs-Oct3/4, pMXs-Sox2, pMXs-Klf4, pMXs-c-Myc) were
obtained from Addgene (Cambridge, MA), and retroviral stocks
were generated using GP2–293 packaging cells (Clontech,
Mountain View, CA). To generate iPSCs from human fibro-
blasts (cultured in DMEM plus 10% fetal calf serum), 2
rounds of viral transduction were performed on 30,000 fibro-
blasts, and cells were incubated with virus for another 48 hours.
After 4 days, cells were passaged and cultured on mitotically
inactivated mouse embryonic fibroblasts (MEFs). iPSC colonies
were manually picked and passaged. Undifferentiated iPSCs
and human embryonic stem cells (hESCs; H7 line; WiCell
Research Institute, Madison, WI) were cultured and passaged
on a MEF feeder layer with daily medium changes (DMEM/
F12, 20% knockout serum replacement, 1mM L-glutamine,
0.1mM nonessential amino acids, 0.1mM b-mercaptoethanol
[Sigma], and 4ng/ml human basic fibroblast growth factor
[bFGF; from Invitrogen except as noted]) in dedicated incuba-
tors (37C, 5% CO2). For teratoma assays, DS and control
iPSCs were cultured on MatriGel-coated dishes (BD Bioscien-
ces, Franklin Lakes, NJ) in MEF-conditioned media. Cells were
dissociated with trypsin, suspended in phosphate-buffered saline
(1 3 107 cells/ml), and subcutaneously injected (200ll) in the
upper hindlimbs of NOD SCID gamma mice (Jackson Labora-
tory, Bar Harbor, ME). After 6 to 8 weeks, tumors were dis-
sected and fixed with 4% paraformaldehyde. Tissues were
embedded in OCT, frozen, sectioned, and stained with hema-
toxylin and eosin. To generate neural progenitor cells (NPCs),
iPSCs were differentiated via embryoid bodies (EBs) for 4 to 5
days and plated on Matrigel-coated dishes in NPC medium
(DMEM/F12, N-2 supplement, 20ng/ml bFGF, nonessential
amino acids, 2mM glutamine, and 2lg/ml heparin [Sigma]).
After 3 weeks, neural rosettes were isolated, and NPCs were
expanded as floating neurospheres. For neuronal differentiation,
neurospheres were dissociated with trypsin, and cells plated on
Matrigel-coated dishes were cultured in differentiation medium
lacking mitogens (Neurobasal plus B27 [Invitrogen], 10ng/ml
brain-derived neurotrophic factor and neurotrophin-3 [Pepro-
Tech, Rocky Hill, NJ]) for 2 months.
Reverse Transcriptase Polymerase Chain
Reaction and Gene Expression Profiling
Total RNA was extracted from iPSCs, hESCs, fibroblasts, and
neural progeny with the RNeasy Mini or Micro kit (Qiagen,
Hilden, Germany) and DNAse I treatment. First-strand cDNA
synthesis was done from 2lg of total RNA using Superscript
III reverse transcriptase (Invitrogen) and random hexamers
according to the manufacturer’s instructions. Polymerase chain
reaction (PCR) was performed in 25ll reactions containing
200nM each of forward and reverse primers, 1 3 PCR buffer,
Taq DNA polymerase, and cDNA template. PCR primer
sequence and annealing temperature are provided in the
Supplementary Table. For reverse transcriptase (RT)-PCR of
sodium channel genes, cDNA was synthesized from 250ng of
total RNA using the Superscript First Strand cDNA Synthesis
Kit (Invitrogen). PCR was performed in 25ll reactions contain-
ing 500nM each of forward and reverse primers, 1 3 PCR
buffer, 200nM deoxyribonucleoside triphosphate, 1U Taq DNA
polymerase (Promega, Madison, WI), and cDNA template.
Amplification was carried out with an initial 3-minute denatu-
ration at 94C, followed by 35 cycles of 45 seconds at 94C,
45 seconds at 60C, and 45 seconds at 72C, and terminating
with a 10-minute extension reaction at 72C. The forward
primer SCN1Ax13 is located in exon 13, and the reverse primer
SCN1Ax15 is located in exon 15; this primer pair amplifies a
343 base pair (bp) fragment from the wild-type transcript and
a 169-bp fragment from the DS1 transcript lacking exon 14
(174 bp in length). To obtain gene-specific amplification of so-
dium channel transcripts, primer pairs were designed with the
30 terminus of 1 or both primers terminating on 1 to 2 bases
that are specific to 1 gene in the sodium channel family (see
Supplementary Table). Sodium channel primers designated F
and R are located in the penultimate and final exon of each
gene, respectively. Amplified fragments were sequenced to con-
firm specificity. Quantitative RT-PCR for exogenous Oct4,
Klf4, Sox2, and c-Myc was performed with the SYBR Green
qPCR reagent (Applied Biosystems, Foster City, CA) containing
200nM each of forward and reverse primers and template using
a Bio-Rad (Hercules, CA) iCycler PCR machine. For microar-
rays, total RNA (400ng) was labeled with the Total Prep RNA
amplification kit (Ambion), and biotin-labeled complementary
RNA (750ng) was prepared for hybridization to the Illumina
(San Diego, CA) HumanHT-12 v4 Expression BeadChip.
Chips were washed, labeled with Cy3, scanned into an Illumina
BeadArray Reader, and analyzed with GenomeStudio
(Illumina).
Immunocytochemistry and Microscopy
Cultures were fixed with 4% paraformaldehyde for immunocy-
tochemistry. For immunostaining involving nuclear and cyto-
plasmic proteins, cells were permeabilized with 0.2% Triton
X-100. Antibodies used were: Pax6 (1:100; Developmental
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Studies Hybridoma Bank, University of Iowa)), Musashi
(1:500; Chemicon, Temecula, CA), FORSE-1 (1:1,000; Chemi-
con), Otx2 (1:500; R&D Systems, Minneapolis, MN), En1
(1:500; Chemicon), Oct3/4 (1:200; Santa Cruz Biotechnology,
Santa Cruz, CA), Nanog (1:500; Chemicon), SSEA-4 (1:200;
Chemicon), SMA (1:1,000; Sigma), a-fetoprotein (1:500;
Dako, Carpinteria, CA), b-III-tubulin (TuJ1 clone, 1:2,000;
Covance, Emeryville, CA), microtubule-associated protein
(MAP) 2ab (1:1,000; Sigma), Tbr-1 (1:400; Abcam, Cam-
bridge, MA), c-aminobutyric acid (GABA; 1:3,000; Sigma), ve-
sicular glutamate transporter-1 (VGLUT1; 1:4,000; Chemicon),
parvalbumin (1:400; Abcam), calretinin (1:2,000; Chemicon),
calbindin (1:500; Abcam), somatostatin (1:300; Millipore), ty-
rosine hydroxylase (1:400; Chemicon), vimentin (1:1,000;
MBL International, Woburn, MA), GFAP (1:1,000, Sigma),
and S-100b (1:400; Swant, Marly, Switzerland). Conjugated
secondary antibodies were applied, and nuclei were counter-
stained with bisbenzimide. Stained cells were viewed and
imaged using epifluorescence microscopy (DM IRB; Leica,
Wetzlar, Germany) and a SPOT RT digital camera (SPOT
Imaging Solutions, Sterling Heights, MI).
Statistical Analysis
Voltage clamp data were tested for normality using the Sha-
piro–Wilk test. Continuous variables with normal distribution
were compared using 2-tailed Student t test or analysis of var-
iance. Current clamp data from patient and control iPSCs were
compared using Student t test. Values were considered statisti-
cally significant at p 0.05.
Results
A Novel Loss-of-Function SCN1A Splice Site
Mutation in a 7-Year-Old Patient with DS
The first subject’s seizures began at age 9 months, his de-
velopment subsequently regressed, and he experienced
multiple types of pharmacoresistant seizures. Diagnostic
sequencing identified a heterozygous splice donor site
mutation IVS1413A>T (Fig 1A). This mutation substi-
tutes a pyrimidine at the important 13 position that is
occupied by a purine (G or A) at >95% of human splice
sites. The subject’s parents do not carry the mutation
(data not shown), consistent with a de novo pathogenic
mutation, as is frequently seen in DS.6 RT-PCR of RNA
from the cultured fibroblasts using primers in exon 13
and exon 15 yields 2 major products, the product of the
wild-type allele that contains exon 14 and the mutant
product that skips exon 14 (see Fig 1B). The identity of
RT-PCR products was confirmed by sequencing. Using
primers in exon 11 and exon 15, a less abundant tran-
script that skips both exons 13 and 14 was detected (data
not shown). Because exon 14 contains 174 bp, the open
reading frame is maintained in the mutant transcript, but
the predicted protein product has deletion of
transmembrane segments 2 and 3 in domain 2, with pre-
dicted loss of channel function (see Fig 1C).
To test the function of the mutant channel, we
expressed either wild-type human SCN1A cDNA or a
cDNA lacking the codons from exon 14 in Xenopus
oocytes and recorded whole-cell sodium currents under
voltage clamp. Consistent with previous findings,26 injec-
tion of RNA encoding wild-type human SCN1A resulted
in the expected whole-cell sodium currents (see Fig 1Di).
In contrast, injection of the mutant RNA failed to pro-
duce any detectable current (see Fig 1Dii). We next trans-
fected mammalian tsa-201 cells with cDNA encoding
wild-type or mutant SCN1A and performed immunoblots
of cell lysates. Robust expression of Nav1.1 channel pro-
tein was obtained with wild-type SCN1A, but the mutant
Nav1.1 protein was not detectable above background (see
Fig 1E, F), although we cannot exclude expression of a
markedly truncated, nonfunctional protein. Together,
these findings demonstrate that the mutant protein is
unstable and does not produce functional channels at the
cell membrane. We also expressed mutant and wild-type
channel alone or in combination in tsa-201 cells and
found no current expressed by mutant channel alone, and
no influence of the mutant channel on wild-type current
to suggest a dominant-negative effect (data not shown).
Thus, this patient is heterozygous for a null allele of
SCN1A, as characteristic for DS.6
Generation of DS Patient and Control iPSCs
and Neurons
Heterologous expression systems provide only limited
data regarding the actual function of a mutant channel
in the cells of physiological interest, which in the case of
epilepsy are forebrain neurons. Moreover, differences in
genetic background both between and within species may
substantially influence neuronal ion channel function.27
To characterize the net in vivo effect of the SCN1A
mutation in the genomic background of genetic modi-
fiers, we chose to study the functional effects of DS
patient SCN1A mutations using the subjects’ own neu-
rons via the iPSC method. Primary fibroblasts were
derived from skin biopsies obtained from 2 DS subjects
(both aged 7 years) and 3 unaffected controls (aged 1,
10, and 25 years), and were reprogrammed by retroviral-
mediated gene transfer of Oct4, Sox2, Klf4, and
cMyc.14,15 We initially worked with fibroblasts from the
DS patient carrying the IVS1413A>T mutation
described above, and the majority of our results are from
this subject (DS1). We subsequently reprogrammed cul-
tured fibroblasts from an additional subject with DS
(DS2) who has a c.975T>A SCN1A nonsense mutation
in tyrosine codon 325, resulting in the premature
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termination codon TAA (Y325X). This mutation trun-
cates the 4-domain sodium channel protein within the
pore loop of domain 1, resulting in a predicted loss of
channel activity. A de novo missense mutation in the
same codon, Y325C, was previously observed in a patient
with DS (SCN1A Variant Database, http://www.molgen.-
vib-ua.be/SCN1AMutations).
Colonies with hESC-like morphology emerged
within 10 to 14 days after fibroblast reprogramming, and
by 30 days they displayed the morphology of pluripotent
stem cells similar to a simultaneously cultured H7 hESC
line (Fig 2 A-D). At 3 to 4 weeks after reprogramming,
colonies were manually picked and individually passaged
onto irradiated MEF feeder cells. RT-PCR analysis of
SCN1A showed that the mutant transcript lacking exon
14 was expressed in DS1 patient-derived iPSCs
(Supplementary Fig 1). Consistent with successful
reprogramming into iPSCs, cells from 4 lines (from
DS1, DS2, and 2 controls) were injected into immuno-
compromised mice and formed teratomas (see Supple-
mentary Fig 1B and data not shown). Reprogrammed
iPSCs lost expression of a fibroblast-associated antigen,
TE-7 (data not shown), and all iPSC clones from DS
patients and controls, unlike the fibroblasts, continuously
expressed pluripotency markers, including Nanog, Oct3/
4, SSEA4, alkaline phosphatase, and others. We also
compared the global gene expression profiles among un-
differentiated patient and control iPSCs, H7 cells, and
fibroblasts that were not reprogrammed. As expected, the
iPSCs showed a gene expression profile that was much
more similar to H7 hESCs than to the original fibro-
blasts from which they were derived. RT-PCR for the
FIGURE 1: SCN1A transcripts in fibroblast cultures from patient DS1 (splice donor site mutation IVS1413 A>T in intron 14). (A)
The mutation is located 3 bp downstream of exon 14. Polymerase chain reaction (PCR) primers are located in exons 13 and
15. (B) Reverse transcriptase PCR products from a Dravet syndrome (DS) patient and control (CON) fibroblasts. In addition to
the wild-type (WT) product of 340 bp that contains exon 14, the patient’s fibroblasts produce a smaller product that skips
exon 14, as confirmed by sequencing. (C) Diagram of Nav1.1 channel protein a subunit, with exon 14 residues in black (arrow).
(D) Traces of 2 electrode voltage clamp recordings from Xenopus oocytes injected with RNA of human WT (i) or IVS1413A>T
DS mutant (ii) SCN1A. Only the WT generates sodium current. Scale bar: vertical5500nA; horizontal520 milliseconds. (E) Im-
munoblots (IBs) of tsa-201 cells transfected with WT or IVS1413A>T mutant (Mut) SCN1A using anti-Nav1.1 antibody. WT
shows strong bands (2 replicates), whereas the mutant shows little or no labeling above the mock-transfected control. a-Tubu-
lin is the loading control. (F) Densitometric quantification of Nav1.1 immunoblots from several separate cultures normalized to
a-tubulin expression. *p<0.001, analysis of variance with Tamhane T2 as post hoc test.
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exogenous transcription factor transgenes used for reprog-
ramming showed marked downregulation after fibroblasts
were converted to iPSCs. Also consistent with a pluripo-
tent cell phenotype, control and patient-derived iPSCs
could be differentiated through EBs to give rise to cells
comprising all 3 embryonic germ layers (see Fig 2I–L
and data not shown).
Because forebrain neurons are the affected cells that
cause disease in DS, we directed the differentiation of
patient and control iPSCs toward a forebrain NPC phe-
notype. Five-day-old EBs were cultured to generate
NPCs. Early NPCs displayed a neural rosette morphol-
ogy and expressed forebrain-specific regionalization
markers but not more caudal central nervous system
markers or a pluripotency gene (Fig 3; Supplementary
Fig 2). Neural rosettes were manually picked, passaged,
dissociated, and differentiated to generate neurons and
glia. Early differentiating cells (2–7 weeks) expressed
neuronal antigens, including neuron-specific b-tubulin
and MAP2 (Supplementary Fig 3B–D), and exhibited
increased expression of 5 voltage-gated sodium channels
predominantly expressed in neurons (see Supplementary
Fig 3A). Approximately 80 to 90% of the neurons dis-
played a bipolar morphology and expression of GABA
characteristic of an interneuron phenotype, whereas
about 10% were pyramidal-shaped and expressed the
VGLUT1 and the forebrain pyramidal cell marker Tbr1
(see Fig 2 and Supplementary Fig 2E). Rare cells
expressed tyrosine hydroxylase, indicative of a monoami-
nergic cell type. To determine the types of interneurons
generated from the iPSCs, we immunostained for differ-
ent forebrain interneuron subtypes and found subsets of
cells expressing calretinin, calbindin, parvalbumin, or so-
matostatin (see Supplementary Fig 3B–D and data not
shown). A predominance of interneurons generated by
pluripotent stem cells is not unusual,28–30 although other
FIGURE 2: Reprogramming Dravet syndrome (DS) patient fibroblasts into induced pluripotent stem cells (iPSCs). (A) Skin bi-
opsy-derived fibroblasts from patient DS1 before reprogramming. (B–D) After 4-factor retroviral reprogramming, pluripotent
stem cell colonies began to form within 10 days (B), and were well developed by 30 days (C), and their morphology was similar
to a human embryonic stem cell (hESC) colony from the H7 line (D). (E–G) Patient-specific iPSCs expressed pluripotency
markers Oct4 (E), stage-specific embryonic antigen-4 (SSEA-4; F), Nanog (G), and alkaline phosphatase (AP; H). (I–L) Differentia-
tion of patient-specific iPSCs through embryoid bodies (I) led to tissue of ectodermal (J), endodermal (K), and mesodermal (L)
lineages. b-tub5neuron-specific b-tubulin; GFAP5glial fibrillary acidic protein; a-FP5 a-fetoprotein; SMA5 smooth muscle
actin. Bisbenzimide (BB) nuclear stain is blue in E-G and J–L. Scale bar5100lm for A–G, 200lm for H–J, 50lm for K, L. [Color
figure can be viewed in the online issue, which is available at www.annalsofneurology.org.]
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culture conditions produce more pyramidal neurons (eg,
Shi et al31). With longer culture durations (7–12 weeks),
there appeared substantial numbers of glia that expressed
glial fibrillary acidic protein, S100 b, and vimentin (data
not shown). Although neuronal RNA splicing may vary
from that of other cell types, we found that iPSC-derived
neurons (herein called induced neurons) from subject
DS1 with the IVS1413A>T mutation retained the
abnormal exon 14 splicing of SCN1A described above
for fibroblasts and iPSCs (see Supplementary Fig 1A).
Increased Sodium Current Density and
Neuronal Excitability in SCN1A Mutant Neurons
To examine whether induced neurons from DS subjects
and controls differed in ways that may predispose to epi-
leptic seizures, we performed whole-cell voltage and
current clamp recordings. We first recorded sodium cur-
rents and measured current densities under voltage clamp
in induced neurons that were differentiated for 5 to 7
days. As expected, given the upregulation of voltage-
gated sodium channel mRNAs (see Supplementary Fig
3A), both bipolar- and pyramidal-shaped neurons from
DS1 (mutant) and controls showed typical sodium cur-
rents (Supplementary Fig 4). No significant differences in
sodium current densities were observed between DS1
and control induced neurons at this time point, or
between bipolar- and pyramidal-shaped neurons within
groups (see Supplementary Fig 4B).
We next measured sodium current densities of
induced neurons after differentiation for 3 to 5 weeks.
Neurons with both pyramidal- and bipolar-shaped mor-
phologies from DS subjects and controls showed sodium
currents that were blocked with the addition of 300nM
tetrodotoxin (TTX; Fig 4; Supplementary Fig 4C), a
finding consistent with neuronal TTX-sensitive sodium
currents. However, we observed significantly increased
(2-fold) mean sodium current densities in 3- to 5-week–
differentiated DS mutant neurons with both pyramidal
and bipolar morphologies derived from DS1 compared
to controls. Induced mutant neurons of both morpholo-
gies derived from DS2 exhibited 3-fold increases in so-
dium current density compared to controls. Sodium
current densities in control neurons remained similar to
the levels measured at 5 to 7 days. No significant differ-
ences in sodium current densities were present between
bipolar- and pyramidal-shaped neurons within groups. In
contrast to current density, the voltage-dependence and
kinetics of current activation and inactivation were not
different between control and mutant induced neurons
(see Supplementary Fig 4D–E).
To examine whether the increase in sodium current
density was associated with altered neuronal excitability
of mutant neurons, we recorded action potentials from
DS mutant and control induced neurons differentiated
for 3 to 7 weeks under current clamp recording condi-
tions. In both mutant and control neurons, action poten-
tials were evoked with stimulation after 4 weeks of
differentiation, with more consistently produced repeti-
tive firing by 5 weeks. DS1- or DS2-derived mutant
induced bipolar and pyramidal neurons differentiated for
5 to 7 weeks exhibited a significantly reduced threshold
for action potential generation and increased repetitive
firing frequency compared to controls (Fig 5; Table 1).
Moreover, mutant pyramidal- and bipolar-shaped neu-
rons frequently displayed spontaneous repetitive firing
and bursting activity that was almost never observed in
control neurons (Supplementary Fig 5; Table 2). Changes
in neuronal excitability in mutant pyramidal and bipolar
FIGURE 3: Neuronal differentiation of Dravet syndrome
patient-specific induced pluripotent stem cells (iPSCs). (A–D)
Mutant iPSCs were differentiated into neural rosettes
(arrows in A–C) that expressed the neural progenitor cell
(NPC) markers Pax6 (B) and Musashi (C), and then were
expanded as neurospheres (D). (E–G) Differentiation of
iPSC-derived NPCs into microtubule-associated protein
(MAP) 21 (green in E, F) induced neurons yielded mostly c-
aminobutyric acidergic (GABAergic) interneurons (red in E,
F), and about 10% pyramidal shaped neurons (arrows in F)
that expressed the vesicular glutamate transporter-1
(VGLUT1) (G); phase image is shown in the left-hand panel
of (G). (H) Rare cells expressed tyrosine hydroxylase (TH).
Bisbenzimide nuclear stain is blue in E, F, H. Scale
bar5200lm for A–C, 100lm for D, 75lm for E–H. [Color
figure can be viewed in the online issue, which is available
at www.annalsofneurology.org.]
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neurons from DS1 and DS2 were virtually identical, and
pooled data for the 2 subjects are shown in Tables 1 and
2. Thus, both loss-of-function mutations in SCN1A
increased neuronal excitability. To confirm that sodium
current densities remained increased in DS induced neu-
rons after 5 to 7 weeks of differentiation, we measured
current densities under voltage clamp in these more
mature neurons. Sodium current densities in bipolar-
and pyramidal-shaped DS1 induced neurons differenti-
ated for 5 to 7 weeks remained significantly increased
compared to control induced neurons of the same matu-
rity (Supplementary Fig 6), and no significant differences
were present between bipolar- and pyramidal-shaped
neurons within groups.
Consistent with the increased sodium current den-
sities shown in Figure 4 and Supplementary Figure 6, the
mutant neurons also displayed more depolarized resting
membrane potentials than those of the control neurons,
although the difference was only significant for bipolar-
shaped cells (see Table 1). However, there were no differ-
ences in other intrinsic membrane electrical properties,
including membrane capacitance and input resistance,
between DS and control induced neurons. All of the cur-
rent and voltage clamp recordings were consistent for 3
sublines from DS1, 2 sublines from DS2, and all 3 con-
trols. Taken together, these data suggest that pyramidal-
and bipolar-shaped DS mutant induced neurons are
hyperexcitable, a result consistent with an in vitro epilep-
tic-like phenotype.
Quantitation of Sodium Channel Transcripts
The level of sodium channel transcripts increases during the
transition from iPSCs to derived neurons (see Supplemen-
tary Fig 3A). To determine whether there was transcrip-
tional upregulation of 1 or more sodium channel genes in
induced neurons from DS patients compared to controls,
we carried out RT-PCR using gene-specific primers for the
5 sodium channel genes that are expressed in these cells:
SCN1A, SCN2A, SCN3A, SCN8A, and SCN9A. None of
the sodium channel transcripts were elevated in patient-
derived neurons compared with control neurons (Fig 6).
These data indicate that the elevated sodium current density
in patient-derived neurons results from a post-transcrip-
tional mechanism.
FIGURE 4: Sodium current (INa) density is increased in pyramidal and bipolar neurons with SCN1A mutations. (A, B) Induced
neurons with pyramidal (A) or bipolar (B) morphology are shown in phase images on the left (i). Representative traces of INa (ii)
recorded using the protocol displayed in the inset are shown, as are bar graphs of the mean INa density from control (Ctrl) and
DS1 and DS2 mutant pyramidal neurons (Aiii; control: black bars, n514; DS1: dark gray bars, n522, p50.012 vs control;
DS2: light gray bars, n56, p50.023 vs control) and bipolar neurons (Biii; control, n525; DS1, n527, p50.048 vs control;
DS2, n55, p50.001 vs control). *p<0.05; **p<0.01. No significant differences in sodium current densities are present
between bipolar and pyramidal neurons within groups (p50.70 and 0.94 for control and DS1, respectively). Error bars indicate
mean6 standard error of the mean.
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Discussion
We used the iPSC method to compare the physiological
properties and sodium channel subunit expression of
forebrainlike neurons from 2 DS subjects and 3 human
controls. Voltage clamp recordings initially (5–7 days)
showed sodium current densities that were not signifi-
cantly different between induced neurons from DS sub-
jects and controls. The neurons were very immature and
lacked action potentials at this early stage; however, with
further maturation in vitro to functional neurons, DS
induced neurons developed significantly greater sodium
current densities than those of controls. These findings
were present in both putative excitatory pyramidal-
shaped neurons and inhibitory neurons with bipolar
morphology. Current clamp recordings showed that DS
induced neurons of both morphologies were hyperexcit-
able compared to controls, with significantly reduced
thresholds for action potential generation and increased
firing frequency, as well as spontaneous repetitive firing
and bursting behavior. These findings indicate that DS
iPSC-derived neurons model an epileptic-like phenotype
with in vitro seizure-like activity.
The functional effects of SCN1A mutations were ini-
tially explored using voltage clamp recordings in heterol-
ogous expression systems such as Xenopus oocytes or non-
neuronal mammalian cell lines.10,11 An inconsistent mix-
ture of loss-of-function and gain-of-function effects of
individual mutations was obtained with this
approach.6,9,32 The advantages of the iPSC approach over
these heterologous expression systems are underscored in
the present study. The mutant channels are present in the
natural host cells without the need for transfection. In
addition, the patient genetic background is maintained,
and therefore the properties of the induced neurons reflect
the net effect of the mutation and genetic modifiers.
Mouse models of DS have been generated by tar-
geted deletion of mouse Scn1a and knock-in of a human
SCN1A premature truncation mutation causing DS.12,13
Homozygous and heterozygous Scn1a null mice display
spontaneous seizures; the homozygotes are ataxic and die
at the beginning of the third postnatal week, whereas
more than half of the heterozygotes survive to adult-
hood.12 Voltage clamp recordings from acutely dissoci-
ated hippocampal neurons derived from heterozygous
and homozygous Scn1a null mice revealed decreased so-
dium current densities in putative interneurons with
bipolar morphology, but not in neurons with pyramidal
morphology.12,13 The interneurons also showed decreased
current-induced repetitive firing and reduced action
potential amplitudes. A compensatory upregulation of
Nav1.3 was seen in homozygous and heterozygous Scn1a
null mice, but this was not sufficient to restore normal
sodium currents in putative interneurons. Similarly, stud-
ies using a knock-in mouse model of DS revealed
decreased bursting of fast-spiking interneurons in in vitro
cortical slices from heterozygotes.13 Together, findings
from these mouse DS models, along with a more recent
study using mice with conditional deletion of Scn1a in
interneuron progenitors,33 led to the interneuron hypoth-
esis of epileptogenesis in DS, whereby decreased
FIGURE 5: Characteristics of evoked action potentials (APs)
and spontaneous firing in human induced neurons from con-
trol and Dravet syndrome (DS) subjects. Top trace in A–D
shows representative APs (solid lines) recorded from control
(A) or DS2 (B) bipolar-shaped cells or control (C) or DS1 (D)
pyramidal-shaped cells cultured for 5 weeks using whole-
cell patch clamp recording in current clamp mode. APs
evoked by injection of threshold depolarizing currents
required much less current for the DS2 bipolar (B; 0.17nA, 1
millisecond) or DS1 pyramidal (D; 0.27nA, 1 millisecond)
induced neurons than for the control bipolar (A; 0.61nA, 1
millisecond) or pyramidal (C; 0.35nA, 1 millisecond) induced
neurons; cells were held at resting membrane potential
(265mV for the control bipolar, 263mV for control pyrami-
dal cells, 255 mV for DS2 bipolar, and 272 mV for DS1 py-
ramidal cells, respectively). Also shown are the responses
evoked by subthreshold depolarizing current injections in
the same cells (dotted lines of the top traces in A–D). Mid-
dle traces in A–D represent repetitive firing evoked by injec-
tion of a long-pulse depolarizing current (0.02nA, 1,500
milliseconds) in the same cells as in the top traces. Note the
higher frequency and more prolonged firing in the DS1 or
DS2 induced neurons (B, D) than in the controls (A, C). Bot-
tom traces in A–D show that no spontaneous firing was
observed in either control bipolar (A) or pyramidal (C)
induced neurons when they were held at resting membrane
potential, but both DS1 and DS2 patient-specific induced
neurons displayed consistent, spontaneous firing with burst-
ing activity at resting membrane potential (B, D). Each trace
is a representative example of 7 to 45 individual cells. Scale
bars540pA for all vertical bars; 10 milliseconds, 400 milli-
seconds, and 10 seconds for horizontal bars of the top, mid-
dle, and bottom traces of each panel, respectively.
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excitability of inhibitory interneurons leads to network
hyperexcitability and seizures.
Our data from human mutant DS iPSC neurons
differ substantially from those in the murine DS models
and do not support the idea of an interneuron-specific
decrease in excitability. We observed increased sodium
current densities and hyperexcitability of both bipolar-
shaped putative inhibitory interneurons and putative py-
ramidal neurons, suggesting an alternative mechanism of
seizure generation that is cell-autonomous and not de-
pendent upon inhibitory innervation. Such a mechanism
is supported by more recent data from a mouse Scn1a
heterozygous knockout DS model, in which sodium cur-
rent density in pyramidal neurons is initially unchanged,
but then significantly increases by the fourth week of
life.34
Our findings raise 2 critical questions. First, what is
the cause of the increased sodium current density in DS
patient-specific neurons? We found that DS and control
sodium currents were similar in immature neurons, and
that sodium currents increase in DS neurons as they
mature. These data suggest a cell autonomous, homeo-
static-like mechanism that overcompensates, perhaps by
overexpression of a different voltage-gated sodium chan-
nel a-subunit or a proexcitatory change in another ion
channel. We did not observe increases in other voltage-
gated sodium channel a subunit expression at the mRNA
level, suggesting that if there is any compensatory
increase in these subunits, it would be through post-tran-
scriptional mechanisms or altered subcellular targeting.
Second, how might the similar changes that we see
in both interneurons and pyramidal cells cause epilepsy?
The most plausible explanation is that increased excitabil-
ity of both principal and inhibitory neurons leads to
network hyperexcitability or synchronization sufficient to
produce seizures and cognitive dysfunction. This effect
might be analogous to the administration of a chemo-
convulsant, such as kainic acid, that increases the activity
of both inhibitory and excitatory neurons with the net
outcome of seizure generation. Another possibility is that
early hyperexcitability of neurons during embryonic de-
velopment leads to abnormal neuronal integration and
resultant network hyperexcitability. Some studies have
found minor malformations of cortical development in
DS, but others have not (reviewed in Guerrini et al35).
Another issue relates to the clinical phenomena of
worsening seizures in many DS subjects treated with
sodium-channel blocking anticonvulsants such as lamotri-
gine.36 This phenomenon is not easily explained by a
mechanism involving compensatory increases in sodium
currents, as proposed here. However, there is currently
no direct evidence in any DS model system explaining
this clinical finding, which is not seen in all DS subjects.
Furthermore, the interneuron hypothesis put forward
TABLE 1. Comparisons of Passive and Evoked Membrane Electrical Properties of Bipolar- and Pyramidal-
Shaped Induced Neurons between Control and DS Patients
Group Resting Vm, mV Input Resistance, GX VThreshold, mV AP Amplitude, mV AP Frequency, Hz
B-Ctrl 267.156 1.37 (33) 1.256 0.15 (33) 223.676 1.51 (30) 114.906 4.69 (34) 3.486 0.73 (27)
B-DS 258.556 1.28 (45)a 1.246 0.12 (45) 230.836 1.53 (37)a 121.186 3.26 (37) 11.66 1.33 (37)a
P-Ctrl 263.056 2.72 (9) 1.026 0.34 (9) 220.516 3.37 (8) 125.386 5.14 (8) 5.106 2.66 (7)
P-DS 258.086 1.24 (31) 1.026 0.17 (31) 237.326 1.51 (26)a 114.356 3.97 (26) 12.646 1.99 (24)b
Values are mean6 standard error of the mean; cell numbers are in parentheses.
ap< 0.001,bp< 0.05; Student t test or Mann–Whitney rank sum test.
AP5 action potential; AP Amplitude5 spike height measured from the resting membrane potential level to the peak; AP
Frequency5 frequency of repetitive firing of a given iPSC in response to injection of a 1,500-millisecond depolarizing current
pulse (0.02nA); B-Ctrl5 bipolar-shaped neurons from control iPSCs; B-DS5 bipolar-shaped neurons from DS iPSCs; DS5Dra-
vet syndrome; iPSC5 induced pluripotent stem cell; P-Ctrl5 pyramidal-shaped neurons from control iPSCs; P-DS5pyramidal-
shaped neurons from DS iPSCs; Resting Vm5 resting membrane potential; VThreshold5 threshold membrane potential for evoking
an AP.
TABLE 2. Induced Neurons from Dravet Syndrome
Patients, but Not Controls, Often Display
Spontaneous Bursting Behavior/Repetitive
Firing at Resting Membrane Potential
iPSCs Control (%) DS patient (%)
Pyramidal-shaped 0 (0/7) 68 (19/28)
Bipolar-shaped 4 (1/27) 49 (18/37)
Overall 3 (1/34) 57 (37/65)
DS5Dravet syndrome; iPSC5 induced pluripotent stem
cell.
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based on the initial DS mouse model data also does not
provide an adequate explanation. For example, the argu-
ment is made that if DS interneurons specifically lack
Nav1.1, resulting in decreased sodium current DS, they
would be affected to a greater extent than wild-type neu-
rons by sodium channel blockers. However, one might
just as well argue that pyramidal cells would be more
affected in this situation, because they have higher levels
of sodium current, more channels to block, and thus the
drugs should work better. Additional caveats include the
complicated network effects generated by other likely
homeostatic mechanisms at play, and the often ignored
issue that all of these anticonvulsants have multiple
mechanisms of action.
Human iPSCs provide a remarkable experimental
platform for understanding disease mechanisms and
screening therapeutic drugs using patient-specific cells.
For example, 3 recent studies reported the generation of
patient-specific iPSCs and cardiac myocytes from subjects
with 2 different forms of congenital long QT syndrome
due to potassium channel gene mutations,18,19 and a
third form of long QT syndrome due to a calcium chan-
nel mutation.20 The patient-specific cardiac myocytes
modeled the disease phenotypes remarkably well, with
action potential prolongation, increased in vitro arrhyth-
mogenic potential, and responses to pharmacological
agents that influence cardiac rhythmicity. Several patient-
specific iPSC lines have been generated as models of
other neurological diseases,17,37–39 but the mechanistic
information derived thus far has been limited. A general
limitation of the method is the possible impact of factors
specific to the culture conditions or the state of differen-
tiation of the iPSC-derived neurons. Nonetheless, our
patient-specific DS model suggests that disease-causing
neuronal ion channelopathies are amenable to modeling
with iPSC-derived neurons. In addition to providing new
insight into disease pathogenesis, the iPSC approach
should prove an invaluable tool to evaluate candidate
pharmacological agents using patient-specific cells.
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